SCHEMBL24313840

SCHEMBL24313840

COc1ccc(CNc2ncnc3c2c(-n2cccn2)cn3[C@H]2C[C@H](O)[C@@H](CO)O2)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 3/20 0.44
▸ ADK P55263 1/20 0.44
▸ CYP1A2 P05177 5/20 0.39
▸ CYP3A4 P08684 5/20 0.39
▸ CYP2C19 P33261 5/20 0.39
▸ CLK4 Q9HAZ1 5/20 0.39
▸ CYP2C9 P11712 4/20 0.39
▸ HSD17B10 Q99714 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ TSHR P16473 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ ADORA3 P0DMS8 2/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ CYP2D6 P10635 4/20 0.38
▸ SLC28A2 O43868 1/20 0.38
▸ SLC29A1 Q99808 1/20 0.38
▸ USP2 O75604 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29610890 1.00 METTL3 (0.44) METTL3ADKCYP1A2CYP3A4CYP2C19
SCHEMBL29610840 0.89 METTL3 (0.41) METTL3ADKCYP1A2CYP3A4CYP2C19
SCHEMBL24313842 0.89 METTL3 (0.41) METTL3ADKCYP1A2CYP3A4CYP2C19
SCHEMBL24313843 0.89 METTL3 (0.38) METTL3ADKCYP1A2CYP3A4CYP2C19
SCHEMBL27090405 0.89 METTL3 (0.38) METTL3ADKCYP1A2CYP3A4CYP2C19
SCHEMBL24313850 0.85 PRMT5 (0.47) METTL3ADKCYP1A2CYP3A4CYP2C19
SCHEMBL29610954 0.85 PRMT5 (0.47) METTL3ADKCYP1A2CYP3A4CYP2C19
SCHEMBL29611468 0.85 PRMT5 (0.47) METTL3ADKCYP1A2CYP3A4CYP2C19
SCHEMBL29610880 0.80 METTL3 (0.34) METTL3CYP1A2CYP3A4CYP2C19CLK4
SCHEMBL24313851 0.80 METTL3 (0.34) METTL3CYP1A2CYP3A4CYP2C19CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051985-A1 METTL3 MODULATORS ACCENT THERAPEUTICS INC (US) 2024-02-15 — — US disclosed
EP-4229067-A1 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2023-08-23 — — EP disclosed
WO-2022081739-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
WO-2022081739-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051985-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 METTL3 1/4885ADK 1475/4885CYP1A2 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback